OptiNose, a Yardley, PA (USA)-based specialty pharmaceutical company, completed a Series C-1 round of financing.
Founded in 2000 and led by Peter Miller, Chief Executive Officer, OptiNose has developed AVP-825, a product that, once approved, will be used for the treatment of migraines. The company out-licensed the North American marketing rights for AVP-825 to a partner and jointly submitted a New Drug Application with the U.S. FDA earlier this year. In parallel with that program, OptiNose has actively pursued the development program of OPN-375, a new product with applications in the treatment of serious chronic nasal inflammatory diseases.
Investors in the company, which is also based in Oslo, Norway, and the United Kingdom, include Avista Capital Partners, WFD Ventures LLC and Entrepreneurs Fund LP.